Antje-Christine Walz

Dr. Antje-Christine Walz

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2014 in Cancer Cell
Verified
Journal Article
Closed access
CRCarola H. Ries
Carola H. Ries
MCMichael A. Cannarile
Michael A. Cannarile
SHSabine Hoves
Sabine Hoves
JBJörg Benz
Jörg Benz
KWKatharina Wartha
Katharina Wartha
DRDominik Rüttinger
Dominik Rüttinger

6 October 2015 in mAbs
Verified
Journal Article
Open access
ZLZhe Li
Zhe Li
BKBen-Fillippo Krippendorff
Ben-Fillippo Krippendorff
SSSharad Sharma
Sharad Sharma
AWAntje-Christine Walz
Antje-Christine Walz
TLThierry Lavé
Thierry Lavé
DSDhaval K. Shah
Dhaval K. Shah
Biodistribution coefficients (BC) allow estimation of the tissue concentrations of proteins based on the plasma pharmacokinetics. We have previously established the BC values for monoclonal antibodies. Here, this concept is extended by development of a relationship between protein size and BC values. The relationship was built by deriving the BC values for various antibody fragments of known molecular weight from published biodistribution studies. We found that there exists a simple exponential relationship between molecular weight and BC values that allows the prediction of tissue distribution of proteins based on molecular weight alone. The relationship was validated by a priori predicting BC values of 4 antibody fragments that were not used in building the relationship. The relationship was also used to derive BC50 values for all the tissues, which is the molecular weight increase that would result in 50% reduction in tissue uptake of a protein. The BC50 values for most tissues were found to be ~35 kDa. An ability to estimate tissue distribution of antibody fragments based on the BC vs. molecular size relationship established here may allow better understanding of the biologics concentrations in tissues responsible for efficacy or toxicity. This relationship can also be applied for rational development of new biotherapeutic modalities with optimal biodistribution properties to target (or avoid) specific tissues.

5 August 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
COC. Willemien Menke-van der Houven van Oordt
C. Willemien Menke-van der Houven van Oordt
CGCarlos Gomez-Roca
Carlos Gomez-Roca
CHCarla van Herpen
Carla van Herpen
ACAndrew L. Coveler
Andrew L. Coveler
DMDevalingam Mahalingam
Devalingam Mahalingam
CTChristophe Le Tourneau
Christophe Le Tourneau
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors

22 April 2009 in Journal of Pharmacokinetics and Pharmacodynamics
Verified
Journal Article
Closed access
PDF file
GKGilbert Koch
Gilbert Koch
AWAntje-Christine Walz
Antje-Christine Walz
GLGezim Lahu
Gezim Lahu
JSJohannes Schropp
Johannes Schropp

11 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
NVNorbert Vey
Norbert Vey
JDJacques Delaunay
Jacques Delaunay
GMGiovanni Marconi
Giovanni Marconi
WFWalter Fiedler
Walter Fiedler
EREmmanuel Raffoux
Emmanuel Raffoux
CRChristian Recher
Christian Recher
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

21 January 2015 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
PDF file
DMD R Mould
D R Mould
AWAntje-Christine Walz
Antje-Christine Walz
TLT Lave
T Lave
JGJp Gibbs
Jp Gibbs
BFB Frame
B Frame
Anticancer agents often have a narrow therapeutic index (TI), requiring precise dosing to ensure sufficient exposure for clinical activity while minimizing toxicity. These agents frequently have complex pharmacology, and combination therapy may cause schedule-specific effects and interactions. We review anticancer drug development, showing how integration of modeling and simulation throughout development can inform anticancer dose selection, potentially improving the late-phase success rate. This article has a companion article in Clinical Pharmacology & Therapeutics with practical examples. CPT Pharmacometrics Syst. Pharmacol. (2015) 4, 12–27; doi:10.1002/psp4.16; published online 21 January 2015